PanTher Therapeutics, a pioneer in localized cancer treatment, has announced the appointment of John Edwards as the Executive Chair of its Board of Directors.

Edwards, a seasoned biopharmaceutical executive with over 35 years of experience, is recognized for his role in the development and commercialization of ten FDA-approved biologics and his leadership in eight biotech companies with successful exits.

Laura Indolfi, CEO and co-founder of PanTher, praised Edwards’ contributions since joining the company and expressed enthusiasm for the expertise he brings as they progress PTM-101, their lead program, into later-stage clinical trials.

Edwards’ track record includes transformative roles at Abcuro, Tilos Therapeutics, F-star, and Adnexus, among others, where he significantly increased company valuations and advanced clinical programs.

Edwards commended PanTher’s innovative Sagittari™ platform, which enables high-dose, localized delivery of cancer treatments, enhancing efficacy while minimizing systemic side effects. This technology, developed at MIT, positions PanTher to transform the treatment of locally advanced solid tumors as they prepare for phase 1b clinical trials.

PanTher’s Sagittari™ platform represents a breakthrough in oncology, offering a polymer-based system for the sustained release of therapeutic agents directly to tumors, potentially unlocking the full potential of potent cancer drugs.